Although current treatment that targets the phosphatidylinositol‐3‐kinase/protein kinase B/mammalian target of rapamycin and cyclin D/cyclin‐dependent kinases 4 and 6 signaling pathways, usually in combination with aromatase inhibitors or fulvestrant, have markedly improved the survival of this subset of patients (Araki & Miyoshi, 2018; Layman, 2019), it remains imperative to identify novel potent modulators that regulate the cellular response to endocrine therapy in BC. Here, CYP19A1 is linked to breast cancer.